Moderna Inc.'s (MRNA) shares were down 2.8% in trading on Tuesday. Pfizer Inc. (PFE), which makes a competing COVID-19 vaccine to Moderna's Spikevax, on Tuesday put out guidance for 2023, saying it expects a total of $13.5 billion in sales of its COVID shot for the year. That's a much lower projection than the $37.8 billion in revenue that was generated by Pfizer and BioNTech's (BNTX) COVID vaccine in 2022. Moderna's COVID vaccine is expected to bring in $18.1 billion in sales for 2022 and $7.3 billion in 2023, according to the FactSet consensus. The company is set to report its fourth-quarter results on Feb. 23. Its stock is up 3.3% over the past year, while the broader S&P 500 is down 7.8%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.